Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Powder-based, Needle-free Injection System Market by Product (Jet, Spring, Laser, Vibration), by Application (Cardiovascular Surgeries, General Surgeries, Gynecological Surgeries, Orthopedic Surgeries, Ophthalmic Surgeries, Other) and by End User (Hospitals Clinics, Home Care Settings, Research Laboratories, Pharmaceutical Biotechnological Companies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02358

Pages: NA

Charts: NA

Tables: NA

The needle-free injection is a technology that enables the delivery of drug through skin by employing various drug propelling forces such as shock waves, Lorentz, electrophoresis, or pressure by gas. The technology eliminates the use of hypodermic needles as a drug delivery system. In addition, this technology is utilized for mass immunization programs, by eliminating the chances of needle infection and other complications, which arise from traditional needle delivery systems.

The growth of the global needle free injection system market is driven by increase in prevalence of chronic diseases and rise in occurrences of contagious diseases due to needlestick injuries. Moreover, increase in demand for self-injection systems is expected to propel the growth of the market. However, high development cost of needle-free injection technologies hinder the market growth.

The global needle-free injection system market is segmented on the basis of product, application, end user, and geography. Based on product, the market is divided into jet, spring, laser, vibration. Applications covered in this study include cardiovascular surgeries, general surgeries, gynecological surgeries, orthopedic surgeries, ophthalmic surgeries, and others. By end user, it is divided into hospitals & clinics, home care settings, research laboratories, pharmaceutical & biotechnological companies, and others. Geographically, it is analyzed across North America, Europe, Asia Pacific, and LAMEA. These regions are further analyzed across the globe at country level to determine the market size and forecast for each segment and subsegment of the market.

Comprehensive competitive analysis and profiles of major market players such as Antares Pharma, Inc. Endo International PLC, Pharmajet, Inc., Inovio Pharmaceuticals, Inc., Medical International Technology, Inc., Injex Pharma AG, National Medical Products, Inc., Valeritas, Inc., European Pharma Group, Penject Corporation, and Crossject SA are provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
  • Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework.
  • It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

 Key Market Segments

  • By Product
    • Jet
    • Spring
    • Laser
    • Vibration
  • By Application
    • Cardiovascular Surgeries
    • General Surgeries
    • Gynecological Surgeries
    • Orthopedic Surgeries
    • Ophthalmic Surgeries
    • Other
  • By End User
    • Hospitals & Clinics
    • Home Care Settings
    • Research Laboratories
    • Pharmaceutical & Biotechnological Companies
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Medical International Technology, Inc.
  • Penject Corporation
  • Inovio Pharmaceuticals, Inc.
  • European Pharma Group
  • Pharmajet, Inc.
  • National Medical Products, Inc.
  • Injex Pharma AG
  • Crossject SA
  • Endo International Plc.
  • Valeritas, Inc.
  • Antares Pharma, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Jet

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Spring

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Laser

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Vibration

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Cardiovascular Surgeries

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. General Surgeries

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Gynecological Surgeries

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Orthopedic Surgeries

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Ophthalmic Surgeries

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Other

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals And Clinics

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Home Care Settings

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Research Laboratories

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Pharmaceutical And Biotechnological Companies

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Others

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Powder-based, Needle-free Injection System Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Powder-based, Needle-free Injection System Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Powder-based, Needle-free Injection System Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Powder-based, Needle-free Injection System Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Powder-based, Needle-free Injection System Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Powder-based, Needle-free Injection System Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Powder-based, Needle-free Injection System Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Powder-based, Needle-free Injection System Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Powder-based, Needle-free Injection System Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Powder-based, Needle-free Injection System Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Powder-based, Needle-free Injection System Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Powder-based, Needle-free Injection System Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Powder-based, Needle-free Injection System Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Powder-based, Needle-free Injection System Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Powder-based, Needle-free Injection System Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Powder-based, Needle-free Injection System Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Powder-based, Needle-free Injection System Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Powder-based, Needle-free Injection System Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Powder-based, Needle-free Injection System Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Powder-based, Needle-free Injection System Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Powder-based, Needle-free Injection System Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Powder-based, Needle-free Injection System Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Powder-based, Needle-free Injection System Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Powder-based, Needle-free Injection System Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Powder-based, Needle-free Injection System Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Antares Pharma, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Endo International Plc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Pharmajet, Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Inovio Pharmaceuticals, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Medical International Technology, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Injex Pharma AG

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. National Medical Products, Inc.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Valeritas, Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. European Pharma Group

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Penject Corporation

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Crossject SA

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR JET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR SPRING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR LASER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR VIBRATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR CARDIOVASCULAR SURGERIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR GENERAL SURGERIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR GYNECOLOGICAL SURGERIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR ORTHOPEDIC SURGERIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR OPHTHALMIC SURGERIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOME CARE SETTINGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR RESEARCH LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. U.S. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. U.S. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. U.S. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. CANADA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. CANADA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. CANADA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. MEXICO POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. MEXICO POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. MEXICO POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 34. EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 37. FRANCE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. FRANCE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. FRANCE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. GERMANY POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. GERMANY POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. GERMANY POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. ITALY POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. ITALY POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. ITALY POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. SPAIN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. SPAIN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. SPAIN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. UK POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. UK POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. UK POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. RUSSIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. RUSSIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. RUSSIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. REST OF EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. REST OF EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. REST OF EUROPE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. ASIA-PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. ASIA-PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. ASIA-PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 61. ASIA-PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. CHINA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. CHINA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. CHINA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. JAPAN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. JAPAN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. JAPAN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. INDIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. INDIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. INDIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. SOUTH KOREA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. SOUTH KOREA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 73. SOUTH KOREA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. AUSTRALIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. AUSTRALIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 76. AUSTRALIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 77. THAILAND POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 78. THAILAND POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 79. THAILAND POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. MALAYSIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 81. MALAYSIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 82. MALAYSIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 83. INDONESIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 84. INDONESIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 85. INDONESIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 90. LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 91. LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 92. LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 93. BRAZIL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 94. BRAZIL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 95. BRAZIL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. SOUTH AFRICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. SOUTH AFRICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 98. SOUTH AFRICA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 99. SAUDI ARABIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 100. SAUDI ARABIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 101. SAUDI ARABIA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. UAE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 103. UAE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 104. UAE POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 105. ARGENTINA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 106. ARGENTINA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 107. ARGENTINA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 108. REST OF LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 109. REST OF LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 110. REST OF LAMEA POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM, BY END USER, 2025-2033 ($MILLION)
  • TABLE 111. ANTARES PHARMA, INC.: KEY EXECUTIVES
  • TABLE 112. ANTARES PHARMA, INC.: COMPANY SNAPSHOT
  • TABLE 113. ANTARES PHARMA, INC.: OPERATING SEGMENTS
  • TABLE 114. ANTARES PHARMA, INC.: PRODUCT PORTFOLIO
  • TABLE 115. ANTARES PHARMA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. ENDO INTERNATIONAL PLC.: KEY EXECUTIVES
  • TABLE 117. ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
  • TABLE 118. ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
  • TABLE 119. ENDO INTERNATIONAL PLC.: PRODUCT PORTFOLIO
  • TABLE 120. ENDO INTERNATIONAL PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. PHARMAJET, INC.: KEY EXECUTIVES
  • TABLE 122. PHARMAJET, INC.: COMPANY SNAPSHOT
  • TABLE 123. PHARMAJET, INC.: OPERATING SEGMENTS
  • TABLE 124. PHARMAJET, INC.: PRODUCT PORTFOLIO
  • TABLE 125. PHARMAJET, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. INOVIO PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 127. INOVIO PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 128. INOVIO PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 129. INOVIO PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 130. INOVIO PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: KEY EXECUTIVES
  • TABLE 132. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: COMPANY SNAPSHOT
  • TABLE 133. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: OPERATING SEGMENTS
  • TABLE 134. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: PRODUCT PORTFOLIO
  • TABLE 135. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. INJEX PHARMA AG: KEY EXECUTIVES
  • TABLE 137. INJEX PHARMA AG: COMPANY SNAPSHOT
  • TABLE 138. INJEX PHARMA AG: OPERATING SEGMENTS
  • TABLE 139. INJEX PHARMA AG: PRODUCT PORTFOLIO
  • TABLE 140. INJEX PHARMA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. NATIONAL MEDICAL PRODUCTS, INC.: KEY EXECUTIVES
  • TABLE 142. NATIONAL MEDICAL PRODUCTS, INC.: COMPANY SNAPSHOT
  • TABLE 143. NATIONAL MEDICAL PRODUCTS, INC.: OPERATING SEGMENTS
  • TABLE 144. NATIONAL MEDICAL PRODUCTS, INC.: PRODUCT PORTFOLIO
  • TABLE 145. NATIONAL MEDICAL PRODUCTS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. VALERITAS, INC.: KEY EXECUTIVES
  • TABLE 147. VALERITAS, INC.: COMPANY SNAPSHOT
  • TABLE 148. VALERITAS, INC.: OPERATING SEGMENTS
  • TABLE 149. VALERITAS, INC.: PRODUCT PORTFOLIO
  • TABLE 150. VALERITAS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. EUROPEAN PHARMA GROUP: KEY EXECUTIVES
  • TABLE 152. EUROPEAN PHARMA GROUP: COMPANY SNAPSHOT
  • TABLE 153. EUROPEAN PHARMA GROUP: OPERATING SEGMENTS
  • TABLE 154. EUROPEAN PHARMA GROUP: PRODUCT PORTFOLIO
  • TABLE 155. EUROPEAN PHARMA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. PENJECT CORPORATION: KEY EXECUTIVES
  • TABLE 157. PENJECT CORPORATION: COMPANY SNAPSHOT
  • TABLE 158. PENJECT CORPORATION: OPERATING SEGMENTS
  • TABLE 159. PENJECT CORPORATION: PRODUCT PORTFOLIO
  • TABLE 160. PENJECT CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. CROSSJECT SA: KEY EXECUTIVES
  • TABLE 162. CROSSJECT SA: COMPANY SNAPSHOT
  • TABLE 163. CROSSJECT SA: OPERATING SEGMENTS
  • TABLE 164. CROSSJECT SA: PRODUCT PORTFOLIO
  • TABLE 165. CROSSJECT SA: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET SEGMENTATION
  • FIGURE 2. GLOBAL POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET
  • FIGURE 3. SEGMENTATION POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPOWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET
  • FIGURE 11. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR JET, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR SPRING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR LASER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR VIBRATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 17. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR CARDIOVASCULAR SURGERIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR GENERAL SURGERIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR GYNECOLOGICAL SURGERIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR ORTHOPEDIC SURGERIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR OPHTHALMIC SURGERIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET SEGMENTATION, BY BY END USER
  • FIGURE 24. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: POWDER-BASED, NEEDLE-FREE INJECTION SYSTEM MARKET
  • FIGURE 35. TOP PLAYER POSITIONING, 2024
  • FIGURE 36. ANTARES PHARMA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. ANTARES PHARMA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. ANTARES PHARMA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. ENDO INTERNATIONAL PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ENDO INTERNATIONAL PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ENDO INTERNATIONAL PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. PHARMAJET, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. PHARMAJET, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. PHARMAJET, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. INOVIO PHARMACEUTICALS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. INOVIO PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. INOVIO PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. MEDICAL INTERNATIONAL TECHNOLOGY, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. INJEX PHARMA AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. INJEX PHARMA AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. INJEX PHARMA AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. NATIONAL MEDICAL PRODUCTS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. NATIONAL MEDICAL PRODUCTS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. NATIONAL MEDICAL PRODUCTS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. VALERITAS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. VALERITAS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. VALERITAS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. EUROPEAN PHARMA GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. EUROPEAN PHARMA GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. EUROPEAN PHARMA GROUP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. PENJECT CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. PENJECT CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. PENJECT CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 66. CROSSJECT SA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 67. CROSSJECT SA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 68. CROSSJECT SA: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Powder-based, Needle-free Injection System Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved